Peptide compounding continues to attract attention across the pharmacy industry and from the U.S. Food and Drug Administration (FDA).

In July 2026, FDA convened its Pharmacy Compounding Advisory Committee (PCAC) to consider several peptide-related bulk drug substances for potential inclusion on the 503A Bulks List. The review included substances related to BPC-157, KPV, TB-500, MOTs-C, Emideltide (DSIP), Semax, and Epitalon.

For compounding pharmacies, these developments reinforce an important point: the regulatory landscape surrounding peptide compounding continues to evolve. Understanding which substances may be used is one part of the equation. Pharmacies also need to consider whether their facilities and compounding environments are prepared to support their operations as demand, formularies, and regulatory requirements change. Read More >